<DOC>
	<DOCNO>NCT03050086</DOCNO>
	<brief_summary>An open label feasibility study use BPX-01 topical minocycline gel papulopustular rosacea .</brief_summary>
	<brief_title>Open Label Phase 2 Feasibility Study BPX-01Topical Minocycline Gel Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>1 . Male female subject â‰¥18 year age time consent . 2 . Subjects medical condition , rosacea , opinion investigator , put subject unacceptable risk could interfere study assessment integrity data . 3 . A clinical diagnosis moderate severe ( Grade 3 4 ) facial rosacea ( papulopustular ( Subtype 2 ) mix erythematotelangiectatic ( Subtype 1 ) papulopustular ( Subtype 2 ) ) determine Investigator 's Global Assessment ( IGA ) Visit 1/Screening . 4 . Female subject childbearing potential ( include prepuberty ) willing use effective contraceptive method least 28 day baseline ( Day 0 ) least 28 day last study product administration sterilize samesex partner duration study . Hormonal contraceptive must stable dose least 12 week baseline ( Day 0 ) . Subjects use low dose oral contraceptive must use second form birth control ( e.g. , barrier method condom spermicide ) . Note : Female subject nonchildbearing potential defined follow : 1 . Female subject surgical sterilization ( hysterectomy , bilateral oophorectomy , bilateral salpingectomy , bilateral tubal ligation ) ; 2 . Female subject cessation menses least 12 month folliclestimulating hormone ( FSH ) test confirm nonchildbearing potential ( refer central laboratory reference range menopausal woman ) cessation menses least 24 month without FSH level confirm ; 5 . Female subject childbearing potential must negative urine pregnancy test screen baseline ( Day 0 ) . 6 . Treatment hormonal therapy must stable dose frequency least 12 week baseline ( Day 0 ) must remain stable throughout study . 7 . Subjects use makeup , facial moisturizers , cream , lotion , cleanser and/or sunscreen must use product brands/types minimum period 14 day prior baseline ( Day 0 ) , must agree change brand/type frequency use throughout study must agree use makeup , facial moisturizers , cream , lotion , cleanser and/or sunscreens clinic visit day visit . 8 . Subjects must capable give informed consent write informed consent must obtain prior studyrelated procedure . 1 . Have history skin disease , presence skin condition excessive facial hair PI believe would interfere study 2 . Have moderate severe rhinophyma , severe telangiectasia plaquelike facial edema 3 . Have rosacea conglobata fulminans , corticosteroid induce rosacea facial erythrosis rosacea 4 . Have ocular rosacea severity require systemic treatment 5 . Have history adverse reaction minocycline tetracycline class antibiotic 6 . Have clinically significant chemistry hematology value baseline ALT AST screen great equal 2x normal 7 . Have condition factor PI believe may affect response skin interpretation result 8 . Participated clinical study exposure investigational treatment product within previous 30 day , plan concurrent participation study 9 . Have use face OTC topical medication treatment rosacea within 4 week prior baseline . 10 . Have use prescription topical ( face ) oral antibiotic corticosteroid within 4 week prior baseline . 11 . Have facial procedure chemical peel , laser , microdermabrasion within 8 week prior baseline 12 . Have receive photodynamic therapy phototherapy blue red light within 12 week prior baseline 13 . Have use oral retinoid within 6 month topical retinoid within 3 month prior baseline 14 . Current drug alcohol abuse 15 . Female subject breastfeeding , pregnant planning pregnancy study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>